Beike Biotechnology Co., Ltd. Sustainability Profile
Beike Biotechnology Co., Ltd., commonly referred to as Beike Biotech, is a leading player in the biotechnology sector, headquartered in China. Established in 2005, the company has made significant strides in regenerative medicine, focusing on innovative cell therapies and advanced medical solutions. With a strong presence in major operational regions across Asia and beyond, Beike Biotech is renowned for its unique offerings, including umbilical cord blood stem cell therapies and personalised treatment plans. These core products stand out due to their commitment to safety and efficacy, positioning the company as a trusted name in the industry. Recognised for its pioneering research and development, Beike Biotech continues to achieve notable milestones, solidifying its market position as a frontrunner in the field of regenerative medicine.
DitchCarbon Score
How does Beike Biotechnology Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Beike Biotechnology Co., Ltd.'s score of 20 is lower than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Beike Biotechnology Co., Ltd.'s reported carbon emissions
Beike Biotechnology Co., Ltd., headquartered in China, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Beike may not have established formal commitments to reduce its carbon footprint or engage in industry-standard climate initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). As the biotechnology sector increasingly prioritises sustainability, Beike's absence of emissions data and reduction initiatives may reflect a broader industry context where companies are under pressure to disclose their environmental impact and set ambitious climate goals.
How Carbon Intensive is Beike Biotechnology Co., Ltd.'s Industry?
How Carbon Intensive is Beike Biotechnology Co., Ltd.'s Location?
Beike Biotechnology Co., Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Beike Biotechnology Co., Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
